VY TAU01
Alternative Names: VY-7523; VY-TAU01Latest Information Update: 30 Sep 2024
At a glance
- Originator Voyager Therapeutics
- Class Antidementias; Gene therapies; Monoclonal antibodies
- Mechanism of Action Gene transference; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 28 Jul 2024 Pharmacokinetics and Adverse events data from preclinical studies in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 16 May 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers) in USA (IV) .
- 13 May 2024 Voyager Therapeutics plans a phase Ia trial for Alzheimer’s disease (In volunteers) in 2024